Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Accenture
Harvard Business School
QuintilesIMS
Johnson and Johnson
AstraZeneca
Deloitte
Teva
McKinsey

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208411

« Back to Dashboard

NDA 208411 describes NARCAN, which is a drug marketed by Adapt and Bristol Myers Squibb and is included in five NDAs. It is available from two suppliers. There are seven patents protecting this drug and one Paragraph IV challenge. Additional details are available on the NARCAN profile page.

The generic ingredient in NARCAN is naloxone hydrochloride. There are twelve drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
Summary for 208411
Tradename:NARCAN
Applicant:Adapt
Ingredient:naloxone hydrochloride
Patents:7
Therapeutic Class:Antidotes, Deterrents, and Toxicologic Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 208411
Mechanism of ActionOpioid Antagonists
Medical Subject Heading (MeSH) Categories for 208411
Suppliers and Packaging for NDA: 208411
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NARCAN naloxone hydrochloride SPRAY, METERED;NASAL 208411 NDA Lake Erie Medical DBA Quality Care Products LLC 55700-457 N 55700-457-01
NARCAN naloxone hydrochloride SPRAY, METERED;NASAL 208411 NDA Adapt Pharma Inc 69547-212 N 69547-212-24

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrength4MG/SPRAY
Approval Date:Nov 18, 2015TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Mar 16, 2035Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Mar 16, 2035Product Flag?YSubstance Flag?Delist Request?
Patented Use:USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.
Patent:➤ Try a Free TrialPatent Expiration:Mar 16, 2035Product Flag?YSubstance Flag?Delist Request?
Patented Use:USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Julphar
Deloitte
Farmers Insurance
Cerilliant
Dow
Cantor Fitzgerald
Healthtrust
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot